Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Shahneen Sandhu

ResearcherPublications, citations & collaboration network

Shahneen Sandhu is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 645 works, 36,193 citations, an h-index of 81 and an i10-index of 269.

645
Works
36,193
Citations
81
h-index
269
i10-index

How has Shahneen Sandhu's publication output changed over time?

ScholarIQpublication output · 2015–2021

Output grew100% over the shown period — from 1 works in 2015 to 2 in 2021.

1
1
4
2
2
2
201520162018201920202021

What are the most-cited papers on Shahneen Sandhu?

ScholarIQmost cited works
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain
New England Journal of Medicine. 20202,278 CitationsOPEN ACCESS
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Pérez-López, Daniel Nava Rodrigues, Dan R. Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Núria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed A. Hussain, Robert J. Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono
New England Journal of Medicine. 20152,204 CitationsOPEN ACCESS
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
New England Journal of Medicine. 20181,870 CitationsOPEN ACCESS
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott Williams, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Christopher J. Sweeney
New England Journal of Medicine. 20191,618 Citations
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu
The Lancet Oncology. 20181,163 Citations

Related on ScholarIQ

The University of Melbourne
Institution
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Paper
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Paper
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Paper
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Paper
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Paper
470M+ articles · free account